Resource Summary Report

Generated by NIF on Sep 17, 2026

NOD.Cg-Mcph1$^{Tg(HLA-A2.1)1Enge}$ Prkdc Il2rg/SzJ

RRID:IMSR_JAX:009617
Type: Organism

Proper Citation

RRID:IMSR_JAX:009617

Organism Information

URL: https://www.jax.org/strain/009617

Proper Citation: RRID:IMSR_JAX:009617

Description: Mus musculus with name NOD.Cg-Mcph1$^{Tg(HLA-A2.1)1Enge}$ Prkdc Il2rg/SzJ from IMSR.

Species: Mus musculus

Synonyms: NSG-A2. NOD scid gamma. HLA-A2.1. hu-NSG-A2. A2-NSG. NOD.Cg-Prkdc Il2rg Tg(HLA-A2.1)1Enge/SzJ

Notes: gene symbol note: major histocompatibility complex; class I; A|microcephaly; primary autosomal recessive 1|interleukin 2 receptor; gamma chain|major histocompatibility complex; class I; subtype A2.1|protein kinase; DNA activated; catalytic polypeptide; mutant strain|congenic strain: HLA-A|Mcph1|Il2rg|HLA-A2.1|Prkdc

Affected Gene: major histocompatibility complex; class I; A|microcephaly; primary autosomal recessive 1|interleukin 2 receptor; gamma chain|major histocompatibility complex; class I; subtype A2.1|protein kinase; DNA activated; catalytic polypeptide

Genomic Alteration: transgene insertion 1; Victor H Engelhard|targeted mutation 1; Warren J Leonard|severe combined immunodeficiency

Catalog Number: JAX:009617

Database: JAX Mice and Services

Database Abbreviation: JAX

Availability: live

Organism Name: NOD.Cg-Mcph1$^{Tg(HLA-A2.1)1Enge}$ Prkdc Il2rg/SzJ

Record Creation Time: 20250513T053715+0000

Record Last Update: 20260912T060500+0000

Ratings and Alerts

No rating or validation information has been found for NOD.Cg-Mcph1$^{Tg(HLA-A2.1)1Enge}$ Prkdc Il2rg/SzJ.

No alerts have been found for NOD.Cg-Mcph1$^{Tg(HLA-A2.1)1Enge}$ Prkdc Il2rg/SzJ.

Data and Source Information

Source: Integrated Animals

Source Database: JAX Mice and Services

Usage and Citation Metrics

We found 14 mentions in open access literature.

Listed below are recent publications. The full list is available at NIF .

Kumar N, et al. (2026) Mechanistic insights and in vivo HIV suppression by the BRD4-targeting small molecule ZL0580. PLoS pathogens, 22(2), e1013449.

Wang Y, et al. (2025) Mutation of SMARCA4 Induces Cancer Cell-Intrinsic Defects in the Enhancer Landscape and Resistance to Immunotherapy. Cancer research, 85(11), 1997.

Boardman DA, et al. (2025) Armored human CAR Treg cells with PD1 promoter-driven IL-10 have enhanced suppressive function. Science advances, 11(24), eadx7845.

Seissler J, et al. (2025) Anti-CTLA-4 Treatment Abrogates Co-stimulation Blockade-induced Acceptance of Transgenic Porcine Islets in Humanized Mice. Transplantation, 109(12), e691.

Meraz IM, et al. (2025) NPRL2 gene therapy induces effective antitumor immunity in KRAS/STK11 mutant anti-PD1 resistant metastatic non-small cell lung cancer (NSCLC) in a humanized mouse model. eLife, 13.

Alomar FA, et al. (2025) Diastolic Dysfunction with Vascular Deficits in HIV-1-Infected Female Humanized Mice Treated with Antiretroviral Drugs. International journal of molecular sciences, 26(8).

Kim YM, et al. (2025) Generation of NOD SCID mice with near-complete deletions of Il2rg and Prkdc for human cancer and HSC engraftment. Transgenic research, 34(1), 35.

Steinkamp MP, et al. (2025) Clinical translation of TLR agonist-modified silicified cancer cell therapy supported by humanized mouse models. Molecular therapy. Oncology, 33(4), 201074.

Haderk F, et al. (2024) Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancer. Nature communications, 15(1), 3741.

Xue G, et al. (2024) Clinical drug screening reveals clofazimine potentiates the efficacy while reducing the toxicity of anti-PD-1 and CTLA-4 immunotherapy. Cancer cell.

de Lima PO, et al. (2023) Development of an in vivo murine model of perineural invasion and spread of cutaneous squamous cell carcinoma of the head and neck. Frontiers in oncology, 13, 1231104.

Zeng B, et al. (2023) Skin-Grafting and Dendritic Cell "Boosted" Humanized Mouse Models Allow the Pre-Clinical Evaluation of Therapeutic Cancer Vaccines. Cells, 12(16).

Wang H, et al. (2021) Targeting EphA2 suppresses hepatocellular carcinoma initiation and progression by dual inhibition of JAK1/STAT3 and AKT signaling. Cell reports, 34(8), 108765.

Chew HY, et al. (2020) Endocytosis Inhibition in Humans to Improve Responses to ADCC-Mediating Antibodies. Cell, 180(5), 895.